Trial Assessing the Impact on Facial Skin Quality, Hydration, and Skin Barrier of Three (3) Hydrafacial Treatments in Adults of All Skin Types.

October 13, 2023 updated by: Austin Institute for Clinical Research

A Phase IV Open-label Trial Assessing the Impact on Skin Quality, Hydration, and Barrier of Three (3) Hydrafacial Treatments in Adults of Fitzpatrick Skin Types I-VI

This is a phase IV, unblinded, open-label study assessing the impact on skin quality, hydration, and barrier of three (3) Hydrafacial treatments in healthy adults of Fitzpatrick Skin Types I & II, III, IV, V & VI, 30 to 55 years of age. Efficacy and subject satisfaction will be assessed, before and after three (3) HF treatments, in 6 patient cohorts, each cohort defined by FST I-VI.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

A multisite study. Approximately 30 subjects will be enrolled in the trail. The purpose of this study is to assess the changes in facial skin hydration and moisturization after a series of 3 hydrafacial treatments in subjects of all Fitzpatrick skin types. In addition, patient and investigator assessed changes in skin quality characteristics will be captured. The primary object is Improvement in skin quality assessments performed by the investigator from baseline (prior to treatment 1) to Day 85, the final study visit.

Utilizing patented Vortex Fusion Technology, a pneumatic device, the HydraFacial Syndeo system and HydraFacial Elite MD system cleanses, exfoliates, and hydrates the skin. The procedure lasts 30-45 minutes and includes three steps: a gentle cleansing, followed by a light peel and then infusion of a proprietary blend of ingredients, termed the Regen GF booster, which contains growth factors, humectants and moisturizers. Once this treatment is complete subjects will undergo a non-invasive red LED treatment, Ellipse Red Light, during which the skin is exposed to gentle red light under a horseshoe-shaped illumination device while wearing blocking goggles, to improve circulation and reduce inflammation.

The first visit, including screening and baseline with HF treatment #1, is followed by two additional HF treatments 28 days apart, with a final visit occurring on day 85. PROs, including satisfaction are captured, as well as Investigator-assessed measurements of skin quality (using the validated Scientific Assessment Scale of Skin Quality) including elasticity, roughness, fine lines, pigmentation, erythema, and pore size, Investigator Global Aesthetic Improvement Scale, and Investigator Tolerability Assessment. Additionally, corneometry (a measurement of skin hydration) and tewlometry (a measure of transepidermal water loss, assessing the integrity of the skin barrier) are performed to assess changes with the treatments at selected time points.

All adverse events observed by the study site personnel, or reported spontaneously by the subject, will be recorded, including description, assessment of severity, and relationship to study treatment. Study site will document all serious adverse events that occur (whether or not related to study treatment). The collection period for all SAEs will begin after informed consent is obtained and end after procedures for the final study visit have been completed. The site investigator will report SAEs in accordance with the standard operating procedures and policies of the local Institutional Review Board (IRB).

Subjects are free to withdraw from participating in this study at any time and for whatever reason, specified or unspecified, and without prejudice. Subjects who terminate early will be asked to complete, if possible, all assessments and procedures that would have been conducted on the last study visit.

It is the responsibility of the site investigator to identify and report deviations within 5 working days of identification of the protocol deviation. All deviations must be addressed in study source documents, reported to the study sponsor, and the reviewing Institutional Review Board (IRB) per their policies.

This is an exploratory study for which results will be reported, but not analyzed with statistical tools beyond calculating mean values. No interim analyses will be conducted. This study will use web-based, electronic case report forms (eCRFs) developed through a validated, Electronic Records/Electronic Signatures-compliant platform (US Title 21 CFR Part 11). The Investigator is responsible for all data entered via the remote data capture (RDC) system from the eCRFs and must confirm the accuracy of the data by electronically approving (signing) the eCRFs. The Sponsor will review the database to identify data errors or inconsistencies, which will be posted in the RDC system as queries for resolution.

Study Type

Interventional

Enrollment (Estimated)

30

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • United States
    • Texas
      • Houston, Texas, United States, 77056
        • Austin Institute for Clinical Research, Inc.
        • Principal Investigator:
          • Megan Couvillion, MD
        • Contact:
        • Contact:
        • Sub-Investigator:
          • Helyn Alvarez, MD
      • Pflugerville, Texas, United States, 78660
        • Austin Institute for Clinical Research, Inc.
        • Principal Investigator:
          • Edward L Lain, MD, MBA
        • Contact:
        • Contact:
        • Sub-Investigator:
          • Diana Reyes, PA-C
        • Sub-Investigator:
          • Jennifer J Jordan, PA-C
        • Sub-Investigator:
          • Jennifer Vickers, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  1. Healthy males and females of Fitzpatrick skin types I-VI 30-55 years of age.
  2. No known medical conditions that in the investigator's opinion may interfere with study participation.
  3. Agrees to abstain from starting a new skincare product for the duration of trial participation.
  4. Willingness to cooperate and participate by following study requirements.
  5. Individuals must sign an informed consent and photography consent.

Exclusion Criteria:

  1. History of any cancer excluding fully treated basal cell carcinoma or squamous cell carcinoma in situ in the treatment area.
  2. Presence of untreated precancerous lesions in the treatment area.
  3. Presence of sunburn, moderate to pronounced suntan, uneven skin tone, tattoos, scars or other disfiguration in the treatment area.
  4. Any cutaneous condition that may affect study adherence or ability to assess endpoints, as determined by the investigator, to include, but not limited to, uncontrolled psoriasis, atopic dermatitis, severe photodamage, and uncontrolled acne.
  5. Subject is pregnant, nursing, or planning to become pregnant.
  6. Significant past medical history of hepatic, hypertensive, renal, cardiac, pulmonary, digestive, hematological, neurological, or psychiatric disease, which in the opinion of the Investigator would compromise the safety of the subject.
  7. Currently participating in another clinical trial.
  8. History of Photo Epilepsy.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: HydraFacial Syndeo Treatment
Three HydraFacial Syndeo Treatment will be performed 28 days apart at the Pflugerville site.
Device: HydraFacial Syndeo System
Utilizing patented Vortex Fusion Technology, a pneumatic device, the HydraFacial Syndeo system cleanses, exfoliates, and hydrates the skin.
Drug: ReGen-GF
The Regen-GF Booster, a serum formulated to increase collagen and elastin production, will be used during each HydraFacial treatment using the HydraFacial handpiece and specialized tip for application. Ingredients include Heptapeptide-32 maintains the appearance of healthy, youthful skin through collagen and elastin production, Copper Peptide Cu-GHK regenerates healthy-looking skin by accelerating wound healing and skin repair, Palmitoyl Tetrapeptide-7 treats inflammation while boosting the growth of collagen-producing tissues, Palmitoyl Tripeptide-5 helps skin cells flush toxins while enhancing the appearance of firmness, Azelaoyl Bis-Dipeptide 10 addresses signs of aging by managing the formation of free radicals, K3 Vitamin C promotes collagen synthesis, and Hyaluronic Acid hydrates the skin.
Other: Hydrafacial Elite MD Treatment
hree HydraFacial Elite MD Treatment will be performed 28 days apart at the Houston site.
Drug: ReGen-GF
The Regen-GF Booster, a serum formulated to increase collagen and elastin production, will be used during each HydraFacial treatment using the HydraFacial handpiece and specialized tip for application. Ingredients include Heptapeptide-32 maintains the appearance of healthy, youthful skin through collagen and elastin production, Copper Peptide Cu-GHK regenerates healthy-looking skin by accelerating wound healing and skin repair, Palmitoyl Tetrapeptide-7 treats inflammation while boosting the growth of collagen-producing tissues, Palmitoyl Tripeptide-5 helps skin cells flush toxins while enhancing the appearance of firmness, Azelaoyl Bis-Dipeptide 10 addresses signs of aging by managing the formation of free radicals, K3 Vitamin C promotes collagen synthesis, and Hyaluronic Acid hydrates the skin.
Device: HydraFacial Elite MD System
Utilizing patented Vortex Fusion Technology, the HydraFacial Elite MD system cleanses, exfoliates, and hydrates the skin.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in skin facial skin elasticity, wrinkles, roughness, fine lines, pigmentation, erythema, and pore size
Time Frame: Change from Baseline to Day 85
Measured by Investigator assessment using the validated Scientific Assessment Scale of Skin Quality. the scale assesses the facial skin elasticity, wrinkles, roughness, fine lines, pigmentation, and erythema. The parameters include 0 = none (best possible outcome), 1 = mild, 2 = moderate, 3 = severe, and 4 = very severe (worst possible outcome). Pore size will be measured using parameters of 0 = fine (best possible outcome), 1 = small, 2 = moderate, 3 = large, and 4 = very large (worst possible outcome).
Change from Baseline to Day 85
Change in facial aesthetic appearance
Time Frame: Change from Baseline to Day 85
Measured by the Investigator Global Aesthetic Improvement Scale. Scale and parameters include 1 = worst (worst possible outcome), 2 = mildly improved, 3 = improved, 4 = much improved, and 5 = very much improved (best possible outcome).
Change from Baseline to Day 85
Change in subjective irritation parameters
Time Frame: Change from Baseline to Day 85
Measured by the Investigator Tolerability Assessment. Scale includes burning, stinging, and itching. Each will be measured by the following parameters, 0 = none (best possible outcome), 1 = mild, 2 = moderate, and 3 = severe (worst possible outcome).
Change from Baseline to Day 85
Change in facial skin hydration
Time Frame: Change from Baseline to Day 85
The Corneometry device will be used as a measurement of skin hydration. The values of skin hydration degree is between 0-130 arbitrary units (AU). The higher the value means a better outcome.
Change from Baseline to Day 85
Change in transepidermal water loss
Time Frame: Change from Baseline to Day 85
The Tewlometry device will be used as a measurement of transepidermal water loss. The units of measurement are grams of water per square meter per hour. The higher the value means a better outcome.
Change from Baseline to Day 85

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Austin Institute for Clinical Research

Collaborators

The HydraFacial Company

Investigators

  • Principal Investigator: Edward Lain, MD, MBA, Austin Institute for Clinical Research

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 1, 2023

Primary Completion (Estimated)

May 1, 2024

Study Completion (Estimated)

June 1, 2024

Study Registration Dates

First Submitted

June 15, 2023

First Submitted That Met QC Criteria

June 27, 2023

First Posted (Actual)

July 6, 2023

Study Record Updates

Last Update Posted (Actual)

October 16, 2023

Last Update Submitted That Met QC Criteria

October 13, 2023

Last Verified

October 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • PDCR-000300

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cutis Laxa Facialis

Clinical Trials on HydraFacial Syndeo System

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gabon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe